J’Onco Mentor Version 9.09 — BREAST PRIMARY

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

Explore breast anatomy

Select a breast and quadrant. The utility suggests an ICD-O-3 primary-site code based on the selected region. For overlapping or multifocal patterns, use the documentation and SEER breast coding guidance rather than anatomy alone.

PATIENT RIGHT PATIENT LEFT UIQUOQ LIQLOQ UOQUIQ LOQLIQ

Selected breast & primary site

CALCULATED PRIMARY SITE
Needs selection

Select one or more breast regions.

Select one or more breast regions.

SEER 2026 coding reminder: when invasive tumor is documented in one subsite and in situ tumor in another, code the subsite containing the invasive tumor. Multiple tumors in at least two quadrants may lead to C50.9; a single tumor spanning subsites with origin unknown may lead to C50.8.

Cancer histology and ICD-O-3 coding

Reference traceabilitySEER 2027 Solid Tumor Rules ↗
Type a code or name, or use the dropdown below. Both controls stay synchronized.
ICD-O-3 Morphology / Behavior

8500/2 — Ductal carcinoma in situ (DCIS)

METHOD OF DETECTION (MOD) — BREAST

NCDB/STORE data item 10110. Applies to breast primaries for diagnosis year 2026+.

MOD CODE

—

Short explanation

Select a Method of Detection to display a short coding explanation.

Quick Coding Assistant

Choose the circumstance documented in the diagnostic imaging report.

ODS rule: Code MOD from the diagnostic imaging report. Do not substitute H&P, operative, pathology, or other clinical documentation when the diagnostic imaging report does not document Method of Detection. In that situation, code 99.
Incidental discovery: When breast cancer is discovered incidentally, including during reduction mammoplasty or prophylactic surgery, and the diagnostic imaging documentation supports that circumstance, select 13 — N.

Breast biomarkers & stage-related data

Reference traceabilityNAACCR Breast SSDI ↗

ER, PR, HER2, and Oncotype DX are maintained here as breast prognostic factors. Clinical and pathologic grade are entered in the AJCC Staging section. Residual Cancer Burden is a 2026 SSDI item; verify program requirements and source documentation before coding.

BREAST MULTIPLE PRIMARY RULES & CALCULATOR

Rule review

Apply the Breast Solid Tumor Rules in order and stop at the first applicable rule.

Current Solid Tumor Rule updates matter: separate synchronous ductal and lobular tumors may be multiple primaries when the applicable histologies are on different rows of Table 3. Do not substitute receptor status for histology or primary determination.

AJCC Staging Schema

PATHOLOGIC STAGING CRITERIA — BREAST

Qualifying evidence: Lumpectomy, mastectomy or another qualifying excision generally supports pT. Sentinel-node biopsy or axillary dissection can support pN. Apply special criteria for in situ disease, microinvasion, and treatment before surgery.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

Reference traceabilitySEER*RSA Breast Schema ↗

AJCC Breast: 8th Edition context for 2018–2026

Breast prognostic stage is not determined by T, N, and M alone. Biomarkers and grade can affect the prognostic stage group. This utility displays TNM components and supporting biomarker data rather than producing a definitive prognostic stage group.

CURRENT TNM SELECTION
TX · NX · M0
ANATOMIC STAGE GROUP
Cannot determine

Calculated from the selected AJCC 8th anatomic T, N and M categories. Prognostic stage may differ because grade, ER, PR and HER2 are also used.

Regional lymph nodes — breast

Reference traceability SEER*RSA Breast Regional Nodes ↗

Use the realistic anatomy to review the major breast regional-node groups. Click node-group markers to identify documented involvement. Final cN/pN depends on nodal level, clinical versus pathologic assessment, positive-node count and deposit size.

Detailed breast lymphatic anatomy showing axillary levels I through III, supraclavicular, internal mammary and intramammary lymph nodes

Anatomic context: Level I is lateral to pectoralis minor; Level II is behind/between its borders and includes interpectoral (Rotter) nodes; Level III is medial/apical/infraclavicular. Internal mammary nodes follow the parasternal intercostal spaces. Supraclavicular nodes are regional for breast staging.

Selected regional nodes

None selected.

Suggested anatomic N context: review

Select node groups above or enter the N category in the AJCC Staging section.

EOD — Breast

Reference traceabilitySEER*RSA EOD Breast ↗

EOD Primary Tumor, EOD Regional Nodes, and EOD Mets are separate data items. Breast stage derivation additionally uses specific biomarker and grade data.

EOD Primary Tumor

Use breast-specific extension and size rules from the applicable SEER*RSA version.

EOD Regional Nodes

Use documented regional nodal groups, laterality, and extent. Do not infer an EOD code solely from the simplified node diagram.

EOD Mets

Code documented distant metastatic disease using the schema-specific table.

SEER Summary Stage 2018

0 — In situ

Noninvasive carcinoma confined to the epithelium with no invasion through the basement membrane. Includes in situ breast disease such as DCIS when no invasive component is present.

1 — Localized only

Invasive tumor confined to the breast without qualifying regional direct extension or regional lymph node involvement.

Regional

Select the applicable SEER Summary Stage 2018 Breast regional code.

7 — Distant site(s) / node(s) involved

Distant metastasis or distant lymph node involvement.

9 — Unknown

Insufficient information to assign a Summary Stage category.

Site-Specific Data Items (SSDI)

Reference traceabilityNAACCR Breast SSDI ↗
Breast SSDI / Grade itemWhy it matters
Grade Clinical / PathologicalUsed for staging.
ER SummaryUsed for staging.
PR SummaryUsed for staging.
HER2 SummaryUsed for staging.
Lymph Nodes Positive Axillary Level I-IIUsed for staging.
Oncotype DX Recurrence ScoreStage-related breast data; applicability varies by year and context.
Residual Cancer Burden / RCB Class2026+ SSDI collection context.

Breast Surgery Codes — 2026

SURGERY CODE

B000

None

Breast reconstruction is recorded separately; review the operative report for the most definitive surgery.

Stage & Treatment

Reference traceabilityNCCN Guidelines ↗
High-level treatment learning prompt

Treatment is individualized by stage, receptor status, HER2 status, patient factors, surgery feasibility, and multidisciplinary recommendations.

Educational only; use current treatment guidelines and physician documentation for clinical decision-making.

COMMON METASTATIC SITES — BREAST

Metastatic breast cancer most commonly involves the following distant sites.

COMMON

Bone

A major and very common site of distant breast cancer involvement.

COMMON

Lung

Common distant organ site.

COMMON

Liver

Common distant organ site.

COMMON

Brain

Recognized common site of metastatic breast cancer.

Registrar reminder: Do not infer metastatic disease from symptoms or a typical spread pattern. Use documented imaging/pathology/physician statements and the applicable staging schema.

Sources

2027 standards cycle: Use the current 2027 SEER, STORE, Solid Tumor Rules, NAACCR v27, Summary Stage v3.4, and diagnosis-year applicable staging resources. Historical cases may require prior-year instructions.

Official sources used throughout the Breast Primary page.

\n\n